<div class="headers"><div>Figure 3. Change in radiographic progression by modified Sharp/van der Heijde score from baseline to week 54, by tertiles of CRP levels (A), ESR (B), and swollen joint count (C), averaged over time during the ASPIRE trial. CRP, ESR, and swollen joint counts averaged over time during the trial were estimated by the area under the curve method. - = P < 0.01; i = P < 0.001, versus the MTX plus placebo group. See Figure 1 for definitions and explanation of treatment groups.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p class="">Figure 3. Change in radiographic progression by modified Sharp/van der Heijde score from baseline to week 54, by tertiles of CRP levels (A), ESR (B), and swollen joint count (C), averaged over time during the ASPIRE trial. </p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p class="">CRP, ESR, and swollen joint counts averaged over time during the trial were estimated by the area under the curve method. - = P < 0.01; i = P < 0.001, versus the MTX plus placebo group. See Figure 1 for definitions and explanation of treatment groups.</p></td>
</tr>
</tbody>
</table>
